Novo Nordisk Announces Semaglutide Price Reduct...

By João L. Carapinha

February 26, 2026

Novo Nordisk Drives Semaglutide Price Reduction Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per ...
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Genotype ECG Prediction
Transformative PBM Reform Legislation Signed into Law
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Healthcare Innovation Trends Shaping the Future: Insights from the J.P. Morga...